263 related articles for article (PubMed ID: 36560732)
1. Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients.
Giotis ES; Cil E; Brooke GN
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560732
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.
Ragia G; Manolopoulos VG
Eur J Clin Pharmacol; 2020 Dec; 76(12):1623-1630. PubMed ID: 32696234
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. [Androgens and Antiandrogens influence on COVID-19 disease in men].
Rozhivanov RV; Andreeva EN; Melnichenko GA; Mokrysheva NG
Probl Endokrinol (Mosk); 2020 Oct; 66(4):77-81. PubMed ID: 33351362
[TBL] [Abstract][Full Text] [Related]
6. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Qiao Y; Wotring JW; Zheng Y; Zhang CJ; Zhang Y; Jiang X; Pretto CD; Eyunni S; Parolia A; He T; Cheng C; Cao X; Wang R; Su F; Ellison SJ; Wang Y; Qin J; Yan H; Zhou Q; Ma L; Sexton JZ; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2221809120. PubMed ID: 37459541
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
8. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
10. A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.
Chang CW; Parsi KM; Somasundaran M; Vanderleeden E; Liu P; Cruz J; Cousineau A; Finberg RW; Kurt-Jones EA
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891350
[TBL] [Abstract][Full Text] [Related]
11. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
12. Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Mauvais-Jarvis F
Endocrinology; 2021 Aug; 162(8):. PubMed ID: 34089595
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
Majidipur A; Morin-Dewaele M; Gaspar Lopes J; Berry F; Fouchet J; Bartier S; Dufros Duval A; Soyeux P; Huet E; Louis B; Coste A; Béquignon É; Saldana C; Le Corvoisier P; Destouches D; Pawlotsky JM; de la Taille A; Vacherot F; Bruscella P; Firlej V
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834705
[TBL] [Abstract][Full Text] [Related]
15. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
17. Targeting TMPRSS2 in SARS-CoV-2 Infection.
Baughn LB; Sharma N; Elhaik E; Sekulic A; Bryce AH; Fonseca R
Mayo Clin Proc; 2020 Sep; 95(9):1989-1999. PubMed ID: 32861340
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in COVID-19: the role of androgens in disease severity and progression.
Mohamed MS; Moulin TC; Schiöth HB
Endocrine; 2021 Jan; 71(1):3-8. PubMed ID: 33179220
[TBL] [Abstract][Full Text] [Related]
19. Human ACE2 Polymorphisms from Different Human Populations Modulate SARS-CoV-2 Infection.
Hu P; Bauer VL; Sawyer SL; Diaz-Griffero F
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891433
[TBL] [Abstract][Full Text] [Related]
20. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.
Dong M; Zhang J; Ma X; Tan J; Chen L; Liu S; Xin Y; Zhuang L
Biomed Pharmacother; 2020 Nov; 131():110678. PubMed ID: 32861070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
